Shares of Hiscox Ltd (LON:HSX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is GBX 1,728.50.
Several research analysts have weighed in on HSX shares. Peel Hunt restated an “add” rating and set a GBX 1,960 price objective on shares of Hiscox in a report on Thursday, May 28th. Jefferies Financial Group restated an “underperform” rating and set a GBX 1,148 price objective on shares of Hiscox in a report on Thursday, May 7th. Royal Bank Of Canada restated an “outperform” rating and set a GBX 1,850 price objective on shares of Hiscox in a report on Wednesday. Berenberg Bank upped their price objective on shares of Hiscox from GBX 1,760 to GBX 1,900 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hiscox from GBX 1,600 to GBX 1,800 and gave the stock an “overweight” rating in a report on Tuesday, May 5th.
Get Our Latest Stock Report on Hiscox
Hiscox Trading Up 0.7%
About Hiscox
Hiscox is a global, specialty insurer, listed on the London Stock Exchange and headquartered in Bermuda. We have grown from
our roots as a niche Lloyd’s of London underwriter into a diversified international insurance group operating across direct‑to‑consumer, broker and partner‑distributed retail insurance; large and complex commercial insurance; reinsurance and insurance‑linked strategies.
We currently employ over 3,000 people worldwide across 13 countries and 31 offices. We have a distinctive brand, energised and ambitious teams, a strong balance sheet, and plenty of room to grow in each of our chosen markets and lines of business.
Featured Stories
- Five stocks we like better than Hiscox
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Hiscox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hiscox and related companies with MarketBeat.com's FREE daily email newsletter.
